Photo taken from ESMO/X
Jun 29, 2024, 03:18
Peter Schmid’s findings on atezolizumab and sacituzumab govitecan for advanced TNBC – ESMO
ESMO shared a post on LinkedIn:
“For ESMO members: Breaking Science in Breast Cancer.
Peter Schmid presents his findings on atezolizumab and sacituzumab govitecan for advanced Triple-negative breast cancer (TNBC).
Explore this video and others from this series on OncologyPRO now.”
Additional information
Source: ESMO/LinkedIn
Jun 30, 2024, 16:30
Jun 30, 2024, 16:23
Jun 30, 2024, 16:16
Jun 30, 2024, 15:14